Design and characterization of the tumor vaccine MGN1601

The tumor vaccine MGN1601 was designed and developed for treatment of metastatic renal cell carcinoma (mRCC). MGN1601 consists of a combination of fourfold gene-modified cells with the toll-like receptor 9 agonist dSLIM, a powerful connector of innate and adaptive immunity.02/11/2016
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news